Investors & Media

Webcast ImageWebcast
Q2 2015 Isis Pharmaceuticals Earnings Webcast (Live)
08/04/15 at 11:30 a.m. ET
Q2 2015 Isis Pharmaceuticals Earnings Webcast
Tuesday, August 4, 2015 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
Recent Press ReleasesMore >>
08/03/15Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia
CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with severe heterozygous familial hypercholesterolemia (severe HeFH) met its primary efficacy endpoint, a statistically significant reduction in LDL-cholesterol after 60 weeks of treatment of once weekly injections of 200 mg of KYNAMRO compared to placebo. LDL-cholesterol reduction was similar to that observed in prev... 
Printer Friendly Version
08/03/15AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases
CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its ant... 
Printer Friendly Version
07/29/15Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Publication highlights the therapeutic potential of volanesorsen to address unmet needs in patients with high apoC-III and triglyceride levels CARLSBAD, Calif. and CAMBRIDGE, Mass., July 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating vol... 
Printer Friendly Version
07/28/15Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
- Webcast scheduled on Tuesday, August 4 at 11:30 a.m. Eastern Time CARLSBAD, Calif., July 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss its second quarter 2015 financial results and report on pipeline and business progress.  Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at  A webcast replay will be ... 
Printer Friendly Version
Upcoming EventsMore >>
08/04/15 11:30 a.m. ET
Q2 2015 Isis Pharmaceuticals Earnings Webcast

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.